The QualityStocks Daily Monday, September 3rd, 2024

Today's Top 3 Investment Newsletters

MarketClub Analysis(PSNYW) $0.2940 +114.52%

QualityStocks(SIFY) $0.6611 +99.61%

Premium Stock Alerts(AUUD) $1.1300 +32.13%

The QualityStocks Daily Stock List

Sify Technologies (SIFY)

Greenbackers, StockEarnings, TradersPro, MarketBeat, QualityStocks, Hit and Run Candle Sticks, SmarTrend Newsletters, StockMarketWatch, The Street, SuperBirdStocks, BullRally, InvestorPlace, PennyToBuck, Early Bird, DrStockPick, CoolPennyStocks, Penny Stock Rumble, MicrocapAlliance, CRWEFinance, CRWEWallStreet, Dynamic Wealth Report, ChartAdvisor, BUYINS.NET, HotOTC, Investiv, MadPennyStocks, CRWEPicks, First Penny Picks, PennyStockVille, Wall Street Resources, Trading Markets, The Trading Report, StockTwits, StockRockandRoll, StockRich, StockHotTips, StockEgg, Penny Detectives, SmallCapVoice, MicrocapVoice, PennyStockLocks, PennyOmega, PennyInvest, Zacks, Penny Stock 101, BestOtc, OTCBB Journal, Money and Markets and Stock Traders Chat reported earlier on Sify Technologies (SIFY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sify Technologies Limited (NASDAQ: SIFY) (FRA: IWY1) is focused on providing integrated ICT solutions and services internationally as well as in India.

Sify Technologies Limited has its headquarters in Chennai, India and was incorporated in 1995. The firm changed its name from Sify Limited in 2007 and serves consumers across the globe.

Sify Technologies offers edge, integration, security, managed network, cloud interconnect and data connectivity services and operates in the following segments: Applications integration services, Technology integration services, Cloud and managed services, Data center services and Telecom services.

Sify’s applications integration segment operates online platforms like samachar.com and sify.com and provides maintenance of industry specific applications, sale of digital certificates, content management, supply chain solutions, web development and online assessments. The technology integration segment offers collaborative tools and solutions, end user computing, information security, network integration and data center build services. The cloud and managed segment provides on-demand hosting services as well as onsite and remote infrastructure management systems which support and manage database layers, applications, utility-based on-demand storage services and customer operating systems. In addition, the data center segment offers managed voice services, virtualization and storage services; shared network, hosting and security services; remote backup, server load balancing and regular backup solutions while the telecom services segment provides last mile connectivity services as well as internet protocol based virtual private network services which include remote access applications, extranets and intranets.

Sify Technologies, which operates the biggest multiprotocol label switching network, recently announced that it was planning on expanding its data-center footprint across the cities of Chennai, Noida and Mumbai, which would widen its reach and boost growth and investments.

Sify Technologies (SIFY), closed Tuesday's trading session at $0.6611, up 99.6075%, on 241,849,104 volume. The average volume for the last 3 months is 2.411M and the stock's 52-week low/high is $0.3036/$2.20.

Auddia Inc. (AUUD)

MarketClub Analysis, QualityStocks, The Online Investor, StockWireNews, Small Cap Firm, MarketBeat, Fierce Analyst, BUYINS.NET and 360 Wall Street reported earlier on Auddia Inc. (AUUD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Auddia Inc. (NASDAQ: AUUD) is a technology firm that is engaged in the development of software products for the podcast and audio markets as well as in the provision of digital music solutions.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2011 by Jeffrey J. Thramann. Prior to its name change in November 2019, the firm was known as Clip Interactive LLC. The firm operates in the technology sector, under the software and tech services industry and serves consumers in the U.S. It generates its revenue via subscription fees from consumers who access its cloud-based computing and advertisement services.

The enterprise is currently engaged in the development of an artificial intelligence-based software technology for consumers and firms in audio media. The technology will allow individuals to tune in to AM/FM radio stations without commercials. It has been designed to identify the differences between a song and a commercial and is working on distinguishing between other content, like DJ conversations, sports, news, traffic and weather reports, among others.

The company’s products include an interactive platform for podcasting known as Vodacast, which podcasters can use to allow their listeners to view video via a digital feed that corresponds to their podcast audio. In addition to this, the company also provides a subscription-based commercial-free AM/FM software application dubbed Auddia App.

The firm recently announced that it had made major advancements in its AI-based software technology. This technology is expected to boost the overall performance of the company’s platform and also positively impact user experience, which will encourage more investments into the firm, thus boosting its growth.

Auddia Inc. (AUUD), closed Tuesday's trading session at $1.13, up 32.1328%, on 106,017,793 volume. The average volume for the last 3 months is 18,119 and the stock's 52-week low/high is $0.83/$12.00.

Avalo Therapeutics (AVTX)

QualityStocks, Zacks, Early Bird, MarketBeat and Timothy Sykes reported earlier on Avalo Therapeutics (AVTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avalo Therapeutics Inc. (NASDAQ: AVTX) (FRA: C6K0) is a clinical stage medicine firm that is focused on discovering, developing and commercializing therapeutics for patients with unmet clinical needs in rare genetic, immune-oncology and immunology illnesses.

The firm has its headquarters in Rockville, Maryland and was incorporated in 2011, on January 31st by Solomon H. Snyder, Barbara S. Slusher, Isaac Blech and Blake M. Paterson. Prior to its name change in August 2021, the firm was known as Cerecor Inc. It operates as part of the scientific research and development services industry and serves consumers around the world.

The company uses a precision medicine approach to develop and commercialize highly targeted therapeutics. It operates a bioassay facility in Germantown.

The enterprise’s product pipeline is made up of an anti-light mAb dubbed AVTX-002, which targets immune-inflammatory ailments like moderate-to-severe inflammatory bowel disease and acute respiratory distress syndrome. It also offers an anti-IL-18 mAb, which targets immune-inflammatory and immune-oncology illnesses like Still’s disease and multiple myeloma. Still’s disease is a disorder that’s characterized by arthritis, a rash, high spiking fevers and inflammation. In addition to this, the enterprise also develops AVTX-801, AVTX-802 and AVTX-803, which are therapeutic monosaccharide therapy doses indicated for congenital disorders of glycosylation; and a dual mTORc1/c2 inhibitor dubbed AVTX-006, which targets lymphatic malformations.

The firm is focused on addressing the significant unmet medical need for patients and advancing its programs, having recently expanded its AVTX-002 program. Meeting these needs will not only extend the firm’s consumer reach but also encourage more investments into the firm, which will be good for its growth.

Avalo Therapeutics (AVTX), closed Tuesday's trading session at $7.91, up 13%, on 16,240 volume. The average volume for the last 3 months is 2.712M and the stock's 52-week low/high is $3.9501/$71.04.

LogicMark Inc. (LGMK)

QualityStocks, StockEarnings, Premium Stock Alerts, Cabot Wealth, Penny Stock, Money Wealth Matters, Early Bird, 360wallstreet and 247 Market News reported earlier on LogicMark Inc. (LGMK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LogicMark Inc. (NASDAQ: LGMK) (FRA: 0NIA) (LON: 0KA8) is engaged in the provision of personal emergency response systems, Internet-of-Things technology and health communications devices which create a connected care platform.

The firm has its headquarters in Louisville, Kentucky and was incorporated in 2012, on February 8th by David Charles Tunnell and Gino Miguel Pereira. Prior to its name change in March 2022, the firm was known as Nxt-ID Inc. It operates as part of the security and protection services industry, under the industrials sector. The firm serves consumers around the globe.

The company’s mission is to always apply the latest technologies for improved and new personal emergency response systems to help its consumers enjoy much-deserved independence. It operates through one business segment, called the software and hardware security systems and applications. The company continues to revolutionize the personal emergency response system industry by developing a 2-way voice communication technology that’s directly connected to the medical alert pendant, which improves the quality of life of its wearers significantly.

The enterprise, which operates through its LogicMark LLC subsidiary, manufactures and distributes monitored and non-monitored personal emergency response systems which are sold via monitored security distributors/dealers, healthcare durable medical equipment distributors and the U.S. Department of Veterans Affairs.

LogicMark Inc. (LGMK), closed Tuesday's trading session at $0.2024, up 12.8834%, on 18,753,165 volume. The average volume for the last 3 months is 46,019 and the stock's 52-week low/high is $0.131/$2.54.

Avenue Therapeutics (ATXI)

QualityStocks, MarketClub Analysis, MarketBeat, StocksEarning, Schaeffer's, Zacks, StockMarketWatch, StreetInsider, The Online Investor, TradersPro, Marketbeat.com, INO Market Report, SmallCapVoice, The Stock Dork, 360 Wall Street, Money Wealth Matters, TradersPro Morning, InsiderTrades, FreeRealTime and PoliticsAndMyPortfolio reported earlier on Avenue Therapeutics (ATXI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avenue Therapeutics Inc. (NASDAQ: ATXI) (FRA: 49Y) is a specialty pharmaceutical firm that is engaged in the acquisition, licensing, development and commercialization of products that are mainly used in the intensive/acute care hospital setting.

The firm has its headquarters in New York and was incorporated in 2015, on February 9th. It operates in the healthcare sector, under the biotech and pharma sub-industry. The company is a majority-controlled subsidiary firm of Fortress Biotech Inc., which is a biopharmaceutical firm that is also engaged in the acquisition, development and commercialization of new biotechnology and pharmaceutical products.

The company develops intravenous Tramadol, which is currently undergoing phase 3 clinical trials for the treatment of moderate to severe post-surgical pain. The synthetic dual-acting opioid works by inhibiting noradrenaline and serotonin re-uptake and blocking spinal level nociceptive impulses and could be used as an alternative for conventional opioids. The oral formulation of this candidate is marketed in the U.S. for moderate to severe pain in grown-ups. Its parenteral formulations include subcutaneous and intramuscular formulations. The drug itself is marketed in the U.S. under the Ultram trade name. Ultracet, which is a combination product of acetaminophen and tramadol, is also sold in the U.S.

The firm is pursuing regulatory approval for its IV tramadol drug formulation, after the FDA cited in their Complete Response Letter that they did not find any controls, manufacturing or chemistry issues with its candidate. If successful, the firm will introduce the drug to the market, which will increase its revenue and boost share prices as well encourage more investments into the firm.

Avenue Therapeutics (ATXI), closed Tuesday's trading session at $2.79, up 9.8425%, on 55,392 volume. The average volume for the last 3 months is 33,674 and the stock's 52-week low/high is $2.25/$64.2675.

Finance of America Companies (FOA)

MarketBeat, QualityStocks, Zacks, Trades Of The Day, The Stock Dork, StocksEarning, MarketClub Analysis, InvestorsUnderground, InsiderTrades and Daily Trade Alert reported earlier on Finance of America Companies (FOA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Finance of America Companies Inc. (NYSE: FOA) is a consumer lending platform which connects investors with borrowers.

The firm has its headquarters in Irving, Texas and was incorporated in 2013. It was formed as a result of a merger between Replay Acquisition and Finance of America Equity Capital. The firm serves consumers in the United States.

The company’s vertically integrated lending and services platform seamlessly connects investors with borrowers. Its objective is to accelerate its growth, innovate new products and services, and become a one stop shop to meet all the financial needs of consumers. The company operates through the following segments: Lender services, Commercial originations, Reverse originations, Mortgage originations and Portfolio management. The company’s subsidiaries include Finance of America Reverse LLC and Finance of America Mortgage LLC.

The enterprise has designed a distribution network which enables customers to interact using their preferred method, be it digitally, telephonically, through a broker or in person. It offers a diverse selection of lending products and services, with a focus on investing and loan origination. The enterprise’s products include business purpose loans to residential real estate investors; reverse mortgage loans and traditional mortgage loans to consumers; commercial loans, home improvement loans and home loans.

The company’s Reverse LLC subsidiary recently launched a new website, which will help improve how the company engages with a wide range of its consumers as well as how it showcases its suite of flexible and modern alternative financing solutions. This move will not only strengthen Finance of America’s brand and bring in more opportunities, but also boost its growth, which will be good for its shareholders.

Finance of America Companies (FOA), closed Tuesday's trading session at $7.89, up 8.3791%, on 17,836 volume. The average volume for the last 3 months is 35.427M and the stock's 52-week low/high is $4.103/$16.00.

UTime Ltd (WTO)

QualityStocks and MarketClub Analysis reported earlier on UTime Ltd (WTO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

UTime Ltd (NASDAQ: WTO) is focused on designing, developing, manufacturing and selling communication equipment like mobile phones, accessories and related consumer electronics.

The firm has its headquarters in Shenzhen, the People’s Republic of China and was incorporated in June 2008 by Bo Tang, Junlin Zhou and Minfei Bao. The firm serves consumers around the globe, with a primary focus on Southeast Asia, South Asia, South America, the United States and Africa.

The company’s operations are based in China, with most of its products being sold globally. It operates through a pair of in-house brands, i.e. “Do”, a low-to-mid-end brand which is positioned to target the majority of price-sensitive consumers and grassroots consumers in emerging markets; and “UTime”, a middle-to-high-end label which targets middle class consumers from various emerging markets.

The enterprise’s consumer electronics include batteries, Bluetooth speakers, power banks, chargers and cell phone shells, molds and parts. It also distributes face masks. This is in addition to providing electronics manufacturing services, which include original design manufacturer and original equipment manufacturer services for well-known brands like Quality One Wireless LLC, which is based in Florida; Haier Electronics Group Co. Ltd, which is a Haier Group Corp subsidiary; and TCL Communication Technology Holdings Ltd, which is a TCL Corp subsidiary.

The company is planning to build manufacturing facilities for the production of smart telecom devices in the city of Nanning, China. This move will allow the company to strengthen its research, development and production capabilities while developing its new generation of smart telecom devices and improving its ecosystem in the industry value chain.

UTime Ltd (WTO), closed Tuesday's trading session at $0.0819, up 8.3333%, on 251,740,352 volume. The average volume for the last 3 months is 334,150 and the stock's 52-week low/high is $0.054/$2.49.

Trulieve Cannabis (TCNNF)

QualityStocks, InvestorPlace, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Cabot Wealth, Top Pros' Top Picks, The Street, CannabisNewsWire, Trades Of The Day, Profit Trends, TradersPro, The Online Investor, StreetInsider and Prism MarketView reported earlier on Trulieve Cannabis (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trulieve Cannabis Corp (OTCQX: TCNNF) (CNSX: TRUL) (FRA: T0A) is a medical cannabis firm that is focused on cultivating, processing, selling and distributing medical cannabis products to alleviate seizures, severe and persistent muscle spasms, pain, nausea, loss of appetite, and other symptoms associated with serious medical conditions such as cancer.

The firm has its headquarters in Quincy, Florida and was incorporated in 1940, on September 17th by Kim Rivers. Prior to its name change in September 2018, the firm was known as Exploration Schyan Inc./Schyan Exploration Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm primarily serves consumers in the United States.

The enterprise produces edibles, flower, concentrates, vaporizer cartridges, tinctures, topicals, capsules, dissolvable powders, and nasal sprays under the Muse, Avenue, Cultivar Collection, Roll One, Modern Flower, Loveli, Alchemy, Momenta, Sweet Talk and Co2lors brands. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The enterprise also operates dispensaries in Arizona, Maryland, Georgia, Connecticut, California, West Virginia and Massachusetts; and affiliated dispensaries in Pennsylvania. It also operates cultivation and processing facilities in Colorado, Arizona, Pennsylvania, Florida, Georgia, Maryland, Massachusetts and West Virginia.

Trulieve Cannabis (TCNNF), closed Tuesday's trading session at $9.4, up 8.046%, on 708,105 volume. The average volume for the last 3 months is 13,739 and the stock's 52-week low/high is $3.79/$14.50.

Tianrong Internet Products & Services (TIPS)

TheStreet Daily, Real Pennies and Daily Trade Alert reported earlier on Tianrong Internet Products & Services (TIPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tianrong Internet Products & Services Inc. (OTC: TIPS) is a development-stage firm focused on marketing mobile and other telephone products over the internet.

The firm has its headquarters in Mountainhome, Pennsylvania and was incorporated in 1959, on January 28th. It operates as part of the specialty industrial machinery industry, under the industrials sector. The firm serves consumers around the globe.

The company operates as a subsidiary of Wilton Management Limited.Wilton offers services to clients incorporating investments, wealth management and secured lending, pensions and professional services, with the latter including corporate finance advisory, valuations, M&A, due diligence, IPO and fundraising activities supporting clients. Wilton's network includes associates with extensive healthcare and Med-Tech experience in C-suite positions to be leveraged to advance TIPS' investment objectives.

The enterprise was formed to invest in medical companies, with a primary focus on the Med-Tech and medical device sectors. It intends to seek out and make strategic acquisitions of domestic and international technology businesses, and intellectual property assets in order to further leverage its market presence. The primary target markets for the company’s investments are Europe and the United States.

The enterprise advertises new and refurbished mobile handsets, landline telephones and accessories through search marketing and other internet marketing initiatives. The order goes directly to the supplier and Tianrong Internet Products and Services receives a commission on each sale.

The firm remains committed to bolstering its overall growth while also creating additional value for its shareholders.

Tianrong Internet Products & Services (TIPS), closed Tuesday's trading session at $0.0362, off by 21.1329%, on 1,100 volume. The average volume for the last 3 months is 18.225M and the stock's 52-week low/high is $0.0017/$0.17.

Tilray Brands Inc. (TLRY)

Schaeffer's, InvestorPlace, QualityStocks, StockEarnings, StocksEarning, The Street, MarketClub Analysis, MarketBeat, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CannabisNewsWire, CFN Media Group, CNBC Breaking News, Daily Profit, The Street Report, Early Bird, INO Market Report, StreetAuthority Daily, FreeRealTime, Prism MarketView, Trading Concepts, Tip.us, The Rich Investor, Top Pros' Top Picks, InvestmentHouse, Trading For Keeps, Inside Trading, Eagle Financial Publications, InsiderTrades, Investment House, Investors Alley, AllPennyStocks, Premium Stock Alerts, wyatt research newsletter, Wealth Daily, VectorVest, TradersPledge, TheTradingReport, The Night Owl, StrategicTechInvestor, Money Morning, Rick Saddler, InvestorsObserver Team, Outsider Club, 360 Wall Street, MarketClub, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond, InvestorsUnderground and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alphabet’s (NASDAQ: GOOGL, GOOG) Google is making significant strides in India’s digital payment landscape through its Google Pay platform. By enhancing its partnership with India’s United Payments Interface (“UPI”), Google is introducing innovative features aimed at simplifying and improving financial transactions for millions of users. This move not only strengthens Google’s position in the fintech sector but also aligns with India’s push towards a more inclusive digital economy. The introduction of features like the UPI Circle and the expansion of the UPI voucher program showcases Google’s commitment to making digital payments more accessible.

The UPI Circle feature on Google Pay is a game-changer for users who prefer cash transactions or are hesitant to use digital payments due to barriers such as limited banking access. By allowing users to add friends or family as secondary users, Google is removing significant hurdles to digital payment adoption. This innovative approach not only broadens the user base but also encourages more people to transition from cash to digital transactions, leveraging the widespread reach of mobile technology in India.

Moreover, the expansion of the UPI voucher program and the introduction of ClickPay QR support are indicative of Google’s strategy to offer versatile and user-friendly payment solutions. Initially aimed at facilitating COVID-19 vaccination payments, the UPI Vouchers have now evolved into a broader payment mechanism for various sectors. This flexibility demonstrates Google’s ability to adapt and expand its services to meet the changing needs of consumers and merchants alike.

Financially, Google’s performance metrics such as the price-to-earnings (“P/E”) ratio of approximately 22.36 and the price-to-sales (“P/S”) ratio of about 5.99 reflect investor confidence in the company’s earnings potential and sales growth. The enterprise value to sales (“EV/Sales”) and enterprise value to operating cash flow (“EV/OCF”) ratios further highlight Google’s strong valuation in relation to its sales and operating cash flow. With a low debt-to-equity (“D/E”) ratio of roughly 0.049 and a current ratio of about 2.08, Google exhibits a solid financial foundation, underpinning its ability to invest in growth initiatives like its partnership with India’s UPI.

Google’s collaboration with NPCI Bharat Billpay and partnerships with over 20 of India’s top brands underscore its ambition to dominate the digital wallet space in India. By extending the use of UPI beyond India’s borders, Google is not only facilitating easier remittances between nations but also setting a precedent for the global adoption of digital payment systems. This strategic move not only benefits users and merchants in India but also positions Google as a key player in the international fintech ecosystem.

To view the company’s latest earnings release, visit https://ibn.fm/NGSHM

About Alphabet Inc.

Alphabet is a collection of companies, the largest of which is Google. Larry Page and Sergey Brin founded Google in September 1998 and the company is headquartered in Mountain View, Calif. Billions of people use its wide range of popular products and platforms each day, like Search, Ads, Chrome, Cloud, YouTube and Android. For more information, visit the company’s website at www.ABC.xyz.

Tilray Brands Inc. (TLRY), closed Tuesday's trading session at $1.68, off by 1.7544%, on 19,610,775 volume. The average volume for the last 3 months is 24.557M and the stock's 52-week low/high is $1.50/$3.40.

Alphabet’s (GOOGL)

The Street, InvestorPlace, Kiplinger Today, Zacks, The Online Investor, Schaeffer's, Daily Trade Alert, Investopedia, Trades Of The Day, Market Intelligence Center Alert, Money Morning, Early Bird, MarketBeat, MarketClub Analysis, StreetInsider, Uncommon Wisdom, StreetAuthority Daily, Wealth Insider Alert, Top Pros' Top Picks, Daily Profit, StrategicTechInvestor, Wyatt Investment Research, The Street Report, Wall Street Daily, The Wealth Report, TopStockAnalysts, Money and Markets, CustomerService, AllPennyStocks, Louis Navellier, MarketWatch, StocksEarning, All about trends, Investing Daily, Daily Wealth, TipRanks, ProfitableTrading, Stansberry Research, CNBC Breaking News, INO.com Market Report, Marketbeat.com, Investors Alley, INO Market Report, MarketTamer, MarketArmor.com, Market Intelligence Center, QualityStocks, Darwin Investing Network, Trading Tips, Power Profit Trades, InvestorGuide, Stock Up Featured, InsiderTrades, Options Elite, Barchart, InvestorIntel, Money Wealth Matters, DividendStocks, Cabot Wealth, Total Wealth, The Night Owl, StockEarnings, SmallCapNetwork, Daily Dividends, GorillaTrades, TheOptionSpecialist, WStreet Market Commentary, FreeRealTime, The Daily Market Alert, Insider Wealth Alert, Jon Markman’s Pivotal Point, Dynamic Wealth Report, Investiv, Investing Futures, Short Term Wealth, SmallCap Network, The Weekly Options Trader, Eagle Financial Publications, Investing Signal, Investor Guide, Trader Prep, InvestorsObserver Team, Trade of the Week, Trading Concepts, Market Authority, Average Joe Options, Investing Lab, The Motley Fool, StockMarketWatch, Smartmoneytrading, 24/7 Trader, Jim Cramer, Wealth Daily, TradingPub, Equities.com, The Wall Street Transcript, Investment House, Chaikin PowerFeed, Shah's Insights & Indictments, Financials Trends, Inside Investing Daily, Investing Breakout, Investment U, Earnings360 Newsletter, Stock Barometer, TrendAdvisor, Tradespoon, TradeSmith Daily, Traders For Cash Flow, Top Pros Top Picks, The Trading Report, The Stock Dork, RedChip, BUYINS.NET, ChartAdvisor, Profit Confidential, Lance Ippolito, Mind Over Markets, StockReport, Pennystockmania, CNBC, Contrarian Outlook, Schaeffer’s, bullseyeoptiontrading, BillionDollarClub, Beat The Street, empirefinancialresearch, Earnings360, 360 Wall Street, Day Trade Alert, Candle Stick Forum, Energy and Capital, Economic News Room, Dividend Opportunities, Energy & Resources Digest, StreetAuthority Financial, Rockwell Trading, Roundtable Roundup, SECFilings.com News, SmallCapVoice, Smart Investing Today, Smart Money Press, SmartTrading, Microcapmillionaires, Street Insider, PoliticsAndMyPortfolio.com, Summa Money, SwingTradeOnline, SystemTrading, Technology Profits Daily, Tim Bohen, Tim Sykes, wyatt research newsletter, Stock Gumshoe, Liberty Through Wealth, Greenbackers, HotStockProfits and iDigital Market reported earlier on Alphabet’s (GOOGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The proportion of Americans who use both tobacco and marijuana has been gradually increasing, particularly among older persons, according to a recent study. After analyzing national data spanning 20 years, Duke University School of Medicine researchers caution that combining both drugs can increase the risk to one’s health when compared to using either drug alone.

A reported 6.38% of American adults in 2021 reported using tobacco and marijuana together within the previous month. While this proportion might not seem like much, it is a considerable rise over prior years. The researchers credit this increase to the growing legalization of marijuana in a number of states, which has increased social acceptance and familiarity with cannabis use.

Lead author of the study, Dana Rubenstein, a Duke University researcher and fourth-year medical student, pointed out that the data from 2021 indicates some groups are more likely to utilize both drugs. Co-using tobacco and cannabis was more common among younger adults, those with less education and residents of states that legalized medical cannabis.

Prior research analyzing the patterns of tobacco and cannabis use, separately or in combination, concentrated on data from 2003 to 2012. But in the intervening period, marijuana laws have been relaxed in 24 more states. Most Americans now reside in places where marijuana use for recreational purposes is legal.

The study reviewed data from 708,891 adults surveyed between 2002 and 2021 through the National Survey on Drug Use and Health. Key findings showed that the co-use of tobacco and marijuana steadily rose between 2002 and 2019. Exclusive marijuana use began increasing after 2007, while tobacco use on its own declined during that period.

Interestingly, while most demographic groups experienced an increase in co-use of these substances, young individuals (18 to 25 years of age) went against this trend, with co-use rates falling after 2014. Rubenstein suggests this decline may be due to fewer young adults choosing to use tobacco over the past 20 years.

In contrast, older adults have shown the opposite pattern, with a notable rise in co-use. The most striking increase was observed among adults aged 50 years and above, where co-use jumped from just 0.42% in 2002 to 3.1% in 2019. Among those aged between 26 and 34, the co-use rate nearly doubled from 6.15% to 10.3%. Similarly, those aged between 35 and 49 saw a stable period between 2002 and 2009, followed by a significant uptick, reaching 6.6% in 2019.

The coauthors of the study, Drs. Lauren R. Pacek and F. Joseph McClernon, who were both formerly employed by Duke University, emphasize the significance of developing focused programs to help individuals stop using both drugs. They also note how important it is to distinguish between the purposes of marijuana use — whether they be recreational or medical — and how this affects co-use with tobacco products.

Leading marijuana companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) are likely to delve deeper into the findings of this study in order to tease out any insights that could be beneficial as the companies make strategic plans for the future.

Alphabet’s (GOOGL), closed Tuesday's trading session at $157.36, off by 3.6847%, on 38,945,301 volume. The average volume for the last 3 months is 474,195 and the stock's 52-week low/high is $120.2057/$191.75.

Compass Pathways PLC (CMPS)

InvestorBrandNetwork, QualityStocks, InvestorPlace, MarketBeat, PsychedelicNewsWire, Daily Trade Alert, Top Pros' Top Picks, StreetInsider, Schaeffer's, Prism MarketView, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics are a class of drugs that induce different states of consciousness, with classic psychedelics such as mescaline, psilocybin, DMT and LSD acting as agonists of the 5-HT2A serotonin receptor. Over the last 20 years, we have observed a significant resurgence of studies focused on the use of psychedelics to address beliefs, traumas and behavioral patterns underlying mental-health disorders.

Various studies have centered on re-evaluating the therapeutic potential of psychedelics, including MDMA, ketamine and psilocybin, in treating addiction. Thus far, the studies have demonstrated that psychedelics may be effective, particularly where traditional treatments fall short.

Some studies have determined that psychedelics may be particularly useful in treating addiction. Their findings were reported in the “Journal of Studies on Alcohol and Drugs,” published by researchers at Rutgers University. These studies focused on helping individuals with opioid addiction, alcohol dependence and other substance-use disorders.

The researchers observed promise from psychedelics during trials, suggesting that they could help increase rates of abstinence in comparison to traditional therapy. They also observed that psychedelic-assisted therapy worked faster than the conventional approach, providing lasting benefits to patients after one to three sessions.

University of Toronto’s Dominique Morisano explained that psychedelic-assisted therapy helped consumers and allowed them to have moments that aided in their discovery. Morisano explains that this would be something reasonable to do, noting that individuals with substance-use disorders often use drugs to hide from any unwanted feelings and thoughts they may have.

She added that while patients experienced feelings of effectiveness that made it easier to adopt healthier coping skills and behaviors, no one knew exactly how this substance works. Some posit that psychedelics act through neuroplasticity, which refers to the ability of the brain to reorganize how it’s been wired.

Despite progress made, the protocols and effectiveness still require additional research, with experts noting that these therapies shouldn’t be administered without professional guidance.

In a report, Morisano noted that there were still basic questions that needed answers, such as which protocols were most effective for substance-use disorders and which drugs worked best for substance-use disorder. She added that additional funding would be needed from both private sources and the public, welcoming government funding.

Presently, Morisano emphasized, individuals needed to understand that psychedelics weren’t a do-it-yourself (DIY) treatment for mental-health conditions and substance abuse, and psychotherapy as part of treatment was important. According to her, microdosing on psychedelics alone isn’t enough.

Other researchers who were part of this study include Doris Payer, Brian Rush and Thomas F. Babor.

There’s still plenty to unpack regarding how exactly psychedelics trigger the therapeutic effects that they have been associated with. Hopefully, the ongoing work by various entities such as Compass Pathways PLC (NASDAQ: CMPS) will provide the needed scientific information to help the world to understand how these substances work.

Compass Pathways PLC (CMPS), closed Tuesday's trading session at $7.225, off by 3.4091%, on 701,227 volume. The average volume for the last 3 months is 135,451 and the stock's 52-week low/high is $5.01/$12.75.

The QualityStocks Company Corner

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

The nation's overreliance on foreign sources, adversarial nations for critical minerals and materials poses national and economic security threats, says report

If establishing critical mineral independence is truly a western goal, it is essential that North American nickel mines be discovered, developed

Fathom Nickel is focused on supplying critical minerals to support the new green economy

Early in the Biden-Harris Administration, a first-of-its-kind report was released providing a supply chain assessment for critical minerals that found the nation's "overreliance on foreign sources and adversarial nations for critical minerals and materials posed national and economic security threats" (https://ibn.fm/QOB8b). The report provided several suggestions to rectify the situation, including working with partners and allies to diversify sustainable sources as well as focusing on expanding American mining, which North American-based mining companies such as Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) are working to provide.

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Tuesday's trading session at $0.03, up 7.1429%, on 95,000 volume. The average volume for the last 3 months is 116,492 and the stock's 52-week low/high is $0.0222/$0.2588.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"). The company today announced that its management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST.

To view the webcast of the presentation, visit https://ibn.fm/6ncBJ

To view the full press release, visit https://ibn.fm/4x6cV

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $5.92, up 12.334%, on 152,151 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2588/$.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced a positive Type C meeting with the U.S. Food and Drug Administration ("FDA"). The meeting supported the advancement of Lomecel-B(TM), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial ("ELPIS II") for hypoplastic left heart syndrome ("HLHS"). According to the announcement, Longeveron and the FDA reached foundational alignment on ELPIS II primary and secondary endpoints as well as on the need to submit the company's prespecified Statistical Analysis Plan ("SAP") and Chemistry, Manufacturing and Controls ("CMC") readiness plan, including Lomecel-B(TM) stability and comparability data, for prior review.

"We are pleased to have alignment with FDA on the development pathway for our Lomecel-B(TM) development program in HLHS, which has a devastating impact on patients and their families," commented Wa'el Hashad, CEO of Longeveron. "While we have a lot of work yet to do, the potential for ELPIS II to serve as the foundation for a BLA submission significantly reduces the time to reach submission and potential approval of Lomecel-B(TM) as an HLHS adjunct therapy."

To view the full press release, visit https://ibn.fm/b8wNR

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Tuesday's trading session at $2.06, up 0.9803922%, on 589,453 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.7707/$28.60.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things ("IoT") and cybersecurity sectors, has received new orders valued at $2.6 million from different governments in Europe; the company anticipates fulfilling the orders in the next three months. The company offers PureSecurity Suite, an end-to-end electronic monitoring solution that features state-of-the-art GPS tracking, communication and monitoring technologies, as well as a secure software platform providing real-time tracking and reporting.

"We are delighted to continue strengthening our collaboration with European governments," said SuperCom president and CEO Ordan Trabelsi in the press release. "These repeat orders underscore our customers' confidence in SuperCom's cutting-edge technology and our unwavering commitment to improving public safety. It is also a testament to our team's dedication to delivering high-quality, reliable solutions. . . . Securing the additional orders of over $2.6 million is a significant achievement for SuperCom. It highlights our leadership in the electronic monitoring sector and our ability to consistently meet our clients' evolving needs. We remain committed to ensuring successful project execution and fostering lasting partnerships with governments worldwide."

To view the full press release, visit https://ibn.fm/WanX4

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Tuesday's trading session at $2.88, up 7.0632%, on 287,168 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.55/$22.60.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

A new law introduced in Georgia will help rein in the state's burgeoning legal hemp industry. The law, which goes into effect on Oct. 1, 2024, may change the way consumers consume CBD drinks and edibles such as gummies. While medical cannabis is heavily regulated in the state, legal variations of marijuana including delta-9 THC products have become very popular. State agricultural officials will be accepting comments from the public until Sept. 6, 2024. After they have considered the written comments, they plan to hold hearings to discuss and approve the new rules. In other news, Congress is currently working toward approving a new farm bill that will allow legislators to strip or add regulations at the federal level that could conflict with regulations at the state level. Companies commercializing various CBD products, such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), will be following how regulatory changes at the federal level conflict with or rhyme with state-level CBD laws.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Tuesday's trading session at $0.015, even for the day, on 10,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria's DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months or less.

To view the full press release, visit https://ibn.fm/qcZJU

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $3.65, off by 6.6496%, on 238,554 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.844/$6.85.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

In the decade or so since mobile money services appeared on the scene, they have gained a significant role in the global economy. The continued digitization of commerce, particularly with the launch of Amazon and other online marketplaces, made mobile money use among the general public even more common. These services became even more popular during the coronavirus pandemic as online purchases, home deliveries and curbside pickups became the norm. Mobile payment systems have fundamentally changed financial transactions between businesses and their customers. The proliferation of mobile smartphones in both developed nations and emerging economies has had a hand in propelling mobile money services to the fore of global trade. As a result, multiple industries have now incorporated mobile payments into their operations with mostly positive effects. In southeast Asia and sub-saharan Africa, services such as GCash and M-PESA are widely used and have helped tens of millions of people gain access to the modern economy. China, currently one of the largest economies on the globe, has adopted mobile money with extreme gusto and processed $17 trillion in mobile money transactions in 2022 through WeChat and Alipay alone. For companies with interests in the mobile payments space, such as FingerMotion Inc. (NASDAQ: FNGR), the opportunities for growth currently seem endless and their expansion plans and execution will determine how much of this vast market they corner for themselves.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $2.08, off by 6.3063%, on 197,037 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.63/$7.97.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

The extended product roadmap is part of the company's efforts to strengthen the connection between quantum optimization, AI and Machine Learning ("ML"), in order to bring new Quantum Artificial Intelligence ("AI") solutions to market

D-Wave's annealing quantum computing solutions could play a key role in improving AI/ML with more efficient model training, reduced energy consumption, and faster time-to-solution

The company's Quantum AI solutions could be transformative, bringing a powerful new set of new computing tools for generative AI

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first commercial provider of quantum computers, was featured in a NetworkNewsAudio syndicated broadcast highlighting the company's extended quantum AI product roadmap and enhancements to its Leap(TM) quantum cloud service. The audio broadcast can be heard at: https://ibn.fm/IcPYR.

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $0.9414, off by 6.7921%, on 1,802,050 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.57/$2.44.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN's BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP's Berubicin and new TPI-287 candidate apart from anything else in development for glioblastoma. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation.

"We are an oncology drug-development company," said CNS Pharmaceuticals CEO John Climaco during the podcast. "We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. . . . Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma."

To view the live webcast, visit https://ibn.fm/gCoxz

To view the full press release, visit https://ibn.fm/0eg3M

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.151, off by 3.944%, on 845,504 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0955/$6875.00.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, has entered into definitive agreements for the immediate exercise of certain outstanding warrants. The agreements outline the "purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share," the company stated in the press release. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The announcement noted that PaxMedica will also issue new unregistered warrants to purchase up to 8,846,160 shares of common stock, with an exercise price of $0.20 per share. Gross proceeds from the exercise of warrants is estimated to total $884,616, before deductions and fees. PaxMedica anticipates using the funds from the offering to continue development of its PAX-101 program as well as for working capital and general corporate purposes.

To view the full press release, visit https://ibn.fm/UbpfP

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Tuesday's trading session at $0.1, off by 53.4776%, on 1,163,490 volume. The average volume for the last 3 months is 43,082 and the stock's 52-week low/high is $0.10/$10.26.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals has strengthened its board by appointing Gordon Maxwell, a highly distinguished geologist who brings nearly four decades of experience from major industry players like Noranda, Xstrata, and Glencore

Maxwell's expertise in exploration and sustainable mining, along with his recognized contributions to Indigenous communities, aligns well with Torr's values and project goals

The addition of Maxwell mirrors successful strategies by other mining companies that have enhanced corporate value by assembling diverse, experienced boards, positioning Torr Metals for future growth and value creation

Torr Metals (TSX.V: TMET) has made a strategic move to strengthen its board of directors with the appointment of Mr. Gordon Maxwell, P. Geo. This addition brings a wealth of experience and industry connections to the table, proving to be a valuable resource as Torr advances its copper-gold porphyry and orogenic gold projects within world-class Canadian mining districts.

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Tuesday's trading session at $27.26, off by 1.9953%, on 31 volume. The average volume for the last 3 months is 439 and the stock's 52-week low/high is $24.01/$31.90.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a publicly traded mineral exploration company exploring for high-grade copper and gold deposits in Virginia and Nunavut, Canada, has released an update on drilling activities and geophysical surveys being conducted at the Storm Copper Project, located on Somerset Island, Nunavut. Highlights of the report indicate that drilling has surpassed 20,000 meters with 128 Reverse Circulation ("RC") drill holes and 14 diamond drill holes now completed; the drilling of a moving-loop electromagnetic ("MLEM") anomaly in an untested area south of the Thunder Prospect at Storm has intersected strong visual copper sulfides; and the drilling is continuing unabated. The exploration program is being conducted by American West Metals Limited, ATBHF's partner on the project

"The outstanding results keep coming in from the exploration program conducted by our partner American West at Storm," said Aston Bay CEO Thomas Ullrich in the press release. "The drilling, which has exceeded the planned 20,000 meters of drilling, continues to expand the known areas of copper mineralization with more RC and diamond drill holes underway. In addition, we have made another significant copper discovery, named ‘Squall,' by drilling a blind MLEM geophysical target. This is the second discovery from drilling MLEM anomalies this year. Both discoveries are in the little-explored Southern Graben area where there is no outcropping copper mineralization, spotlighting both the growth potential for a resource at Storm and confirming the effectiveness of MLEM in pointing the way to copper discoveries."

To view the full press release, visit https://ibn.fm/tyABj

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Tuesday's trading session at $0.088484, off by 11.6926%, on 30,950 volume. The average volume for the last 3 months is 36,524 and the stock's 52-week low/high is $0.0364/$0.176.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .